PT3458067T - Tratamento de distúrbios neurológicos - Google Patents

Tratamento de distúrbios neurológicos

Info

Publication number
PT3458067T
PT3458067T PT177258621T PT17725862T PT3458067T PT 3458067 T PT3458067 T PT 3458067T PT 177258621 T PT177258621 T PT 177258621T PT 17725862 T PT17725862 T PT 17725862T PT 3458067 T PT3458067 T PT 3458067T
Authority
PT
Portugal
Prior art keywords
treatment
neurological disorders
neurological
disorders
Prior art date
Application number
PT177258621T
Other languages
English (en)
Original Assignee
Univ Basel
Torqur Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel, Torqur Ag filed Critical Univ Basel
Publication of PT3458067T publication Critical patent/PT3458067T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/153Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT177258621T 2016-05-18 2017-05-17 Tratamento de distúrbios neurológicos PT3458067T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16170107 2016-05-18

Publications (1)

Publication Number Publication Date
PT3458067T true PT3458067T (pt) 2021-04-07

Family

ID=56024138

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177258621T PT3458067T (pt) 2016-05-18 2017-05-17 Tratamento de distúrbios neurológicos

Country Status (25)

Country Link
US (3) US20190284178A1 (pt)
EP (1) EP3458067B1 (pt)
JP (1) JP6991158B2 (pt)
KR (1) KR102472461B1 (pt)
CN (1) CN109475560B (pt)
AU (1) AU2017265383B2 (pt)
CA (1) CA3022753C (pt)
CY (1) CY1124051T1 (pt)
DK (1) DK3458067T3 (pt)
ES (1) ES2863250T3 (pt)
HR (1) HRP20210477T1 (pt)
HU (1) HUE053494T2 (pt)
IL (1) IL263080B (pt)
LT (1) LT3458067T (pt)
MX (1) MX2018014168A (pt)
PL (1) PL3458067T3 (pt)
PT (1) PT3458067T (pt)
RS (1) RS61655B1 (pt)
RU (1) RU2765868C2 (pt)
SG (1) SG11201809792TA (pt)
SI (1) SI3458067T1 (pt)
SM (1) SMT202100177T1 (pt)
TW (1) TWI753912B (pt)
WO (1) WO2017198346A1 (pt)
ZA (1) ZA201807393B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863250T3 (es) * 2016-05-18 2021-10-11 Torqur Ag Tratamiento de trastornos neurológicos
MX2018014167A (es) 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.
SG11202004589SA (en) 2017-11-23 2020-06-29 Piqur Therapeutics Ag Treatment of skin disorders
CN117396470A (zh) * 2021-04-09 2024-01-12 巴塞尔大学 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
EP4320115A1 (en) * 2021-04-09 2024-02-14 Universität Basel Triazine derivative as reversible and irreversible covalent inhibitors of pi3k

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008010221A (es) * 2006-02-09 2009-03-05 Alba Therapeutics Corp Formulaciones para un efector de union ajustada.
TWI498332B (zh) 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
DK2050749T3 (en) 2006-08-08 2018-01-08 Chugai Pharmaceutical Co Ltd PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
AP2775A (en) 2008-05-23 2013-09-30 Wyeth Llc Triazine compounds as P13 kinase and MTOR inhibitors
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
ES2721302T3 (es) 2013-10-04 2019-07-30 Univ Basel Inhibidores de PI3k y mTOR conformacionalmente restringidos
MA40933A (fr) * 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
ES2863250T3 (es) * 2016-05-18 2021-10-11 Torqur Ag Tratamiento de trastornos neurológicos
MX2018014167A (es) * 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.
EP3458035A1 (en) 2016-05-18 2019-03-27 PIQUR Therapeutics AG Treatment of skin lesions

Also Published As

Publication number Publication date
SG11201809792TA (en) 2018-12-28
KR20190008294A (ko) 2019-01-23
ES2863250T3 (es) 2021-10-11
SMT202100177T1 (it) 2021-05-07
CY1124051T1 (el) 2022-05-27
JP6991158B2 (ja) 2022-02-10
AU2017265383A1 (en) 2018-12-13
CN109475560A (zh) 2019-03-15
RS61655B1 (sr) 2021-04-29
PL3458067T3 (pl) 2021-12-13
MX2018014168A (es) 2019-04-29
RU2018140013A3 (pt) 2020-07-09
IL263080B (en) 2022-02-01
CA3022753A1 (en) 2017-11-23
US20220135551A1 (en) 2022-05-05
AU2017265383B2 (en) 2022-07-28
HUE053494T2 (hu) 2021-06-28
US11878972B2 (en) 2024-01-23
RU2018140013A (ru) 2020-06-18
BR112018073579A8 (pt) 2023-01-10
DK3458067T3 (da) 2021-04-06
BR112018073579A2 (pt) 2019-03-19
WO2017198346A1 (en) 2017-11-23
EP3458067A1 (en) 2019-03-27
KR102472461B1 (ko) 2022-11-30
IL263080A (en) 2018-12-31
JP2019519507A (ja) 2019-07-11
EP3458067B1 (en) 2020-12-30
RU2765868C2 (ru) 2022-02-04
US20240343718A1 (en) 2024-10-17
TWI753912B (zh) 2022-02-01
US20190284178A1 (en) 2019-09-19
ZA201807393B (en) 2023-10-25
CN109475560B (zh) 2023-05-02
SI3458067T1 (sl) 2021-07-30
HRP20210477T1 (hr) 2021-05-14
LT3458067T (lt) 2021-04-26
NZ748601A (en) 2024-12-20
TW201808944A (zh) 2018-03-16
CA3022753C (en) 2024-09-24

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL273693A (en) Treatment of inflammatory disorders
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL267818A (en) Methods for treating neurological disorders
ZA201903003B (en) Treatment of neurological diseases
IL267229A (en) Methods of treating ocular disorders
GB201608046D0 (en) Treatment of complement-mediated disorders
IL255506A (en) A method for treating a neurological disease
GB201412578D0 (en) Treatment of neurological diseases
IL314274A (en) Treatment of skin disorders
IL269604A (en) Pentides for the treatment of autoimmune diseases
PL3200828T3 (pl) Kompozycje donosowe do leczenia chorób i zaburzeń neurologicznych i neurodegeneracyjnych
IL263080B (en) Treatment of neurological disorders
GB201612043D0 (en) Composition for treatment of disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
ZA202002910B (en) Treatment of skin disorders
SG11201706952VA (en) Compositions and methods for the treatment of epilepsy and neurological disorders
GB201604359D0 (en) Treatment of tissue disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201715763D0 (en) Treatment of neurological disease
GB201706662D0 (en) Treatment of neurological diseases
GB201808723D0 (en) Treatment of hyperproliferative disorders
GB201706823D0 (en) Treatment of psychological disorders
GB201602641D0 (en) Treatment of fibrotic disorders